Directed new share issue in InDex Pharmaceuticlas Holding AB (SE) — SEK 140 million

Carnegie acted as sole global co-ordinator and joint bookrunner in the directed new share issue of 20,000,000 new shares at a subscription price of SEK 6.98 per share. InDex is a pharmaceutical development company with a clinical stage asset targeting ulcerative colitis in preparation for Phase III. September 2019.